Idazoksan

Idazoksan
(IUPAC) ime
	(±)-2-(2,3-dihidro-1,4-benzodioksin-2-il)-4,5-dihidro-1H-imidazol
Klinički podaci
Identifikatori
CAS broj	79944-58-4
ATC kod	nije dodeljen
PubChem	54459
ChemSpider	49184
UNII	Y310PA316B
ChEMBL	CHEMBL10316
Hemijski podaci
Formula	C11H12N2O2
Mol. masa	204,225 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C11H12N2O2/c1-2-4-9-8(3-1)14-7-10(15-9)11-12-5-6-13-11/h1-4,10H,5-7H2,(H,12,13) ; Key: HPMRFMKYPGXPEP-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	nije kontrolisan
Način primene	Oralno

Idazoksan je lek koji se koristi u naučnim istraživanjima. On deluje kao selektivni antagonist α2 adrenergičkog receptora i imidazolinskog receptora.^[5]^[6] Idazoksan je istraživan za potencijalnu primenu kao antidepresiv, ali nije plasiran na tržište. On je takoše ispitivan za moguću primenu kao dodatni tretman u lečenju šizofrenije. Usled njegovog dejstva kao alfa-2 antagonist, on ima sposobnost pojačavanja terapeutskih efekata antipsihotika.

Reference uredi

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Bousquet, P; Bruban, V; Schann, S; Greney, H; Ehrhardt, JD; Dontenwill, M; Feldman, J (1999). „Participation of imidazoline receptors and alpha(2-)-adrenoceptors in the central hypotensive effects of imidazoline-like drugs”. Annals of the New York Academy of Sciences 881: 272–8. DOI:10.1111/j.1749-6632.1999.tb09369.x. PMID 10415925.
↑ Clarke, RW; Harris, J (2002). „RX 821002 as a tool for physiological investigation of alpha(2)-adrenoceptors”. CNS Drug Reviews 8 (2): 177–92. PMID 12177687.

Vidi još uredi

Spoljašnje veze uredi

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[5] Bousquet, P; Bruban, V; Schann, S; Greney, H; Ehrhardt, JD; Dontenwill, M; Feldman, J (1999). „Participation of imidazoline receptors and alpha(2-)-adrenoceptors in the central hypotensive effects of imidazoline-like drugs”. Annals of the New York Academy of Sciences 881: 272–8. DOI:10.1111/j.1749-6632.1999.tb09369.x. PMID 10415925.

[6] Clarke, RW; Harris, J (2002). „RX 821002 as a tool for physiological investigation of alpha(2)-adrenoceptors”. CNS Drug Reviews 8 (2): 177–92. PMID 12177687.

[5]

[6]

[1]

[2]

[3]

[4]